Impact of Sodium-glucose Cotransporter-2 Inhibitor Initiation in a Safety-net Hospital
In conclusion, the benefits of SGLT2i drugs reducing SBP, albuminuria, and HbA1c observed in clinical trials were duplicated in our safety-net population. Therefore, ongoing education and promotion to providers to ensure broadened utilization and timely renal function monitoring appear warranted.
Source: Critical Pathways in Cardiology - Category: Cardiology Tags: Original Study Source Type: research
More News: Cardiology | Cardiovascular | Chemistry | Clinical Trials | Education | Heart | Laboratory Medicine | Primary Care | Sodium | Study | Universities & Medical Training | Urology & Nephrology